Insilico Medicine has entered a drug discovery collaboration with Eli Lilly, utilizing Insilico’s AI technology to expedite the development of novel oral therapeutics across various therapeutic areas. The agreement grants Lilly an exclusive worldwide license for these therapeutics, with Insilico eligible for an $115 million upfront payment and potential total deal value of approximately $2.75 billion, including royalties. This partnership combines Insilico’s advanced AI capabilities with Lilly’s expertise, aiming to identify innovative therapies to address significant health challenges.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.manilatimes.net/2026/03/30/tmt-newswire/pr-newswire/insilico-medicine-announces-global-rd-collaboration-with-lilly/2310108
